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Summary
As a consequence of the improvement in diag-
nosis and therapy, many more young women
will survive their cancer. For some of them,
due to toxic treatments, there is the risk of
compromising their reproductive function.
There is a growing body of evidence about the
specific effects of different chemotherapy
drugs on the ovary, based on in vitro methods,
complementing clinical information regard-
ing ovarian function. This information, high-
lighting the varying effects of these drugs on
the different cells and tissues of the ovary, is
reviewed here.
KEY WORDS: chemoterapy, ovary, fertility,
preservation, follicle.
Introduction
Fertility lifespan is directly correlated with the
number of quiescent primordial follicles present
in the ovary. Around the time of birth, this ovar-
ian reserve contains around a million such folli-
cles. The number then steadily declines until on-
ly around a thousand remain, at which time the
menopause occurs, at the average age of 50
years, with fertility rates declining over the pre-
vious two decades (1, 2). In developed coun-
tries, due to both economic and social factors,
motherhood is becoming progressively post-
poned to an age at which fertility is naturally de-
clining. This average older age for childbearing
is matched with a significant increase in the in-
cidence of cancer (3). This means that every
year many more women will be diagnosed with
a new cancer during a fertile age, when they
may have not yet started or at least completed
their families. The effectiveness of cancer treat-
ment has however greatly improved, especially
for childhood cancers. With longer term survival
rates so much better, increasing importance is
now placed on attaining a good quality of life
after treatment. Effects on fertility are key
amongst factors affecting this, and have been
acknowledged as a major stressor for cancer sur-
vivors (4, 5). Exposure to highly cytotoxic treat-
ments during chemotherapy could negatively af-
fect reproductive function via several possible
pathways, primarily the ovary, but also poten-
tially the hypothalamic-pituitary system or the
uterus (Figure 1). It is clear that the ovary is the
prime site of adverse effects of chemotherapy on
female reproductive function, so this review will
focus primarily on this aspect.
Chemotherapy-induced premature 
ovarian insufficiency
The principal and most vulnerable targets of
chemotherapy within the female reproductive
system are the ovaries, the functional units of
which are the ovarian follicles. Each ovarian
follicle is composed of a single female germ
cell, oocyte, arrested in prophase I of the first
meiotic division and surrounded by supportive
somatic cells, the granulosa cells (GCs).
Oocytes surrounded by a single layer of flat-
tened GCs form the quiescent primordial follicle
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(PF) pool. This store of resting follicles is
formed before birth, leading to a limited and ir-
replaceable supply of female germ cells by
birth. Every day, a tiny fraction of the remaining
PFs are activated to leave the resting state and
undergo growth initiation. The subsequent
process of growth and maturation involves nu-
clear and cytoplasmic oocyte maturation as well
as modifications in GCs, which become actively
replicating cuboidal cells, stratifying into multi-
ple layers that interact with the oocyte through
paracrine signalling. Very few activated follicles
will fully mature to ovulate, with the majority
instead undergoing atresia, thus there are pro-
gressively fewer follicles at each stage of
growth. 
The cytotoxic effect of chemotherapy could
damage a variety of cell types within the ovary,
acting directly on follicles and/or on the sur-
rounding stromal or vascular tissue. Similarly,
within follicles, drugs could act primarily on the
oocyte and/or on somatic granulosa or possibly
theca cells. Any of these could lead to a reduc-
tion of gonad functionality through a depletion
of the follicle number or interference with nor-
mal growth. Currently, one important hypothesis
as to how loss of developing follicles results in
depletion of the ovarian reserve is that damage
to developing follicles results in increased acti-
vation of the resting PFs, such that they, in turn,
will be in the growing stage of follicle develop-
ment during subsequent chemotherapy doses,
leading to a resulting dramatic decrease in PF
numbers after several cycles of treatment: this is
sometimes termed the ‘burnout’ theory (6). The
degree of ovototoxicity varies with the thera-
peutic regime, but will also produce different
age-dependent outcomes. In women near to
menopause, iatrogenic reduction of the ovarian
reserve will be more immediately evident be-
cause of the already naturally depleted popula-
tion of follicles; in such women, menopause is
increasingly likely immediately or shortly after
chemotherapy. In younger women, after a cer-
tain period of amenorrhea, fertility could well be
restored for several years, giving a reproductive
window to cancer survivors. Nonetheless,
menopause could then occur precociously, po-
tentially not leaving enough time for family
planning and also affecting the woman’s long-
Figure 1 - Chemotherapeutic drugs are effective against malignant cells, but can also have an adverse impact on healthy
tissues. When this damage occurs to the reproductive system, it is often evident in the ovaries, where the follicle reserve
may be destroyed. In addition, drug toxicity could induce dysfunction in other organs, such as the uterus or the hypothal-
amus and pituitary gland. The possible decrease of reproductive potential generates great concerns about motherhood
among cancer survivors. 
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term health (7). Menopause usually occurs
around the age of 50: when it occurs before the
age of 40, it is termed premature ovarian insuf-
ficiency (POI) (8, 9). POI is related to a higher
incidence of osteoporosis as well as to cardio-
vascular disorders, which could in turn increase
mortality rates (10).
When a cancer therapy is administered to a child
or prepubertal girl, there is potentially a very
wide time interval before the appearance of
symptoms of its deleterious action, from imme-
diately to perhaps 2 or 3 decades later. One ma-
jor issue in the assessment of chemotherapeutic
damage on fertility results from this, namely the
time required for thorough follow-up. A follow-
up study should ideally examine aspects of fer-
tility such as pregnancy, childbirth and timing of
menopause. However, obtaining data on such
end points would require following patients for
decades. When viewed in this way, at this point
very few studies carried out can truly be consid-
ered long term although the US base Childhood
Cancer Survivor Study (CCSS) is a major exam-
ple and has resulted in a wealth of data [for ex-
ample (11-13)]. Others have also contributed to
this (14) but most studies use more short-term,
indirect markers of fertility (reviewed in 9). To
further complicate the situation, chemotherapy-
induced amenorrhea (CIA) is the most widely
used marker of POI, but its definition varies be-
tween studies in terms of period of onset and du-
ration. More importantly, though, neither its oc-
currence, nor its subsequent reversion, is equiv-
alent to infertility/fertility respectively. 
Anti-Mülleran hormone (AMH) level has
proved the most reliable, albeit indirect, marker
of the ovarian reserve (15). AMH blood levels
predominantly derive from small antral folli-
cles, mainly 5-8mm in diameter (16). In contrast
with other hormonal markers (e.g. FSH and
estradiol), AMH levels do not vary significantly
throughout the menstrual cycle. Furthermore,
AMH concentration appears to be a good indi-
rect marker of the ovarian reserve, with levels
falling as women approach menopause or when
ovotoxic treatment is applied (17). The peak in
serum AMH is at age 24, with a progressive rise
through childhood, puberty and early adulthood.
While AMH may be of value in predicting re-
productive lifespan (18, 19), it is of very limited
value in predicting short-term fertility. Pregnan-
cy in the presence of very low AMH level in
post cancer patients has been reported (20), and
in healthy young women low AMH is not asso-
ciated with reduced time to pregnancy (21).
Ovarian damage is not only related to patient
factors such as age, but also to the therapeutic
regimen to be administered. The majority of the
chemotherapeutic drugs act against malignant
cells by interfering with DNA replication, syn-
thesis and repair, breaking double strands and
disrupting the mitotic spindle. As such, treat-
ment is based on the knowledge that cancer cells
divide more rapidly than most other cell types.
However, these same mechanisms of action are
also cytotoxic for other tissues that have a phys-
iologically high rate of cellular turnover. This
leads to a plethora of side effects, one of which
is on the reproductive system. Although factors
such as drug class and dose, and the number of
cycles of chemotherapeutic drugs administered,
are strictly controlled, the effects that they can
produce on human fertility are not easy to as-
sess. Virtually all therapeutic regimens use drug
combinations. As such, the role of individual
drugs, as well as their synergistic effects, are
difficult to assess, although some chemothera-
peutic compounds have been classified as more
gonadotoxic than others (22). Below, we review
the drug class with the best understood and ma-
jor effects on female reproduction, namely alky-
lating and alkylating-like drugs. Many more
drugs are currently used in malignancy treat-
ment, but unfortunately for most of them, lack
of knowledge renders it difficult to assign the
degree of ovotoxicity.
Alkylating and alkylating-like agents
Alkylating agents include some of the most cy-
totoxic compounds known and the ones mostly
responsible for ovarian damage. Their major
mechanism of action is to bind alkyl groups to
DNA, with consequential damage that becomes
particularly evident during subsequent cell
replication. Because tumour cells have a high
mitotic rate, they are less capable of repairing
this damage than healthy cells, hence they are
particularly likely to undergo cell death. The
alkylating agent cyclophosphamide (CTX) is
frequently used in the treatment of many solid
and haematological tumours. Both human and
animal studies have shown variable results, with
different studies showing CTX damaging either
the oocyte or the GCs of growing follicles (23-
26). Significant damage has also been observed
in the ovarian stromal tissue of patients treated
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with alkylating agents, resulting in cortical
blood vessel fibrosis (27). In a cohort study on
105 survivors examined on average 16 years af-
ter childhood cancer diagnosis, ovarian markers
(ovarian volume and AMH level) were lower
than those of control patients. Those markers,
plus antral follicle count, were particularly af-
fected in patients that had received very high
doses of alkylating agents (CTX, ifosfamide and
procarbazine). Significantly, only 8 of 105 pa-
tients had evidence of altered ovarian function
(7). The CCSS also reported a significant corre-
lation between increasing dose of alkylating
agents and failure to achieve pregnancy (12).
Platinum-based agents such as cisplatin, carbo-
platin and oxaliplatin are considered to have
alkylating-like properties, and are also essential
compounds in many cancer therapies, including
lung, breast, ovarian and colon cancers. They
mainly act by binding to DNA and forming
adducts which disrupt DNA transcription and
replication and induce apoptosis (28). The effect
on fertility caused by platinum-based therapy
seems still unclear and is mainly considered as
moderate (29, 30). A follow-up study performed
over 15 years on malignant ovarian germ cell tu-
mour patients who underwent fertility-sparing
surgery showed that the probability of pregnan-
cy significantly decreased as a consequence of
cumulative doses of cisplatin-based therapy
(31).  Similarly, a German survey found a sig-
nificant association between platinum-derived
treatment and risk of infertility in female child-
hood cancer survivors in a study that followed
patients up for around 20 years after treatment
(32). Interestingly, in contrast with the other sur-
vey (12), Reinmuth et al. (32) did not find a cor-
relation between CTX and infertility, but this is
thought likely to be because they excluded pa-
tients from the study whose CTX-based thera-
peutic regimen was known to induce infertility,
such as those with Hodgkin lymphoma.  Several
animal studies have confirmed that cisplatin can
induce ovarian toxicity (33, 34). We have shown
that exposure of mouse ovaries to cisplatin in
vitro induces oocyte damage in early growing
but not PFs: PF numbers are nonetheless drasti-
cally reduced, data that support the ‘burnout’
theory (35).
Therapeutic regimens for haematologic tumours
such as Hodgkin lymphoma and of other cancers
including brain tumours (36) require several cy-
cles of aggressive chemotherapy using a drug
combination that often include procarbazine
(PCZ). PCZ is metabolised in vivo, with its main
metabolite inducing single-strand DNA breaks.
Use of PCZ has frequently been associated with
high rates of infertility (37), with one cohort
study on 706 women treated for childhood can-
cer showing that the presence of PCZ in the
therapeutic regimen increases the risk of early
menopause by 150% for every gram of PCZ re-
ceived by the patient (14). There is a study
presently on going in childhood and adolescent
Hodgkin lymphoma assessing whether replacing
PCZ with dacarbazine might be equally effec-
tive but less toxic (38). A French follow-up
study of childhood cancer survivors indicated
that administration of melphalan alongside PCZ
and CTX further increased the risk of POI (14).
Melphalan is mainly used in the treatment of
myeloma and retinoblastoma; its use seems to
be related to better recovery of fertility when ad-
ministered alone (39). 
Sanders et al. (40) hypothesized that high dose
of alkylating agents in bone marrow transplant
patients increased the incidence of preterm de-
livery and low birth weight (LBW) of the new-
borns. More recently, there has been an indica-
tion that only the highest doses of alkylating
agents might increase the risk of preterm birth
(13), although the effect they found did not
reach statistical significance, and LBW was on-
ly the consequence of early birth that their study
indicated. If there is an effect on subsequent off-
spring, the cause of that effect is unclear, and
could be also a consequence of stress in the
mother-to-be survivor of the childhood cancer:
certainly, stress effects such as this have been
shown after several other kinds of emotional
stressful conditions (13, 41).
Chemotherapy effects on the 
non-ovarian reproductive system 
Radiotherapy is the major cause of damage
caused by cancer treatment on reproductive tis-
sues other than the ovary. This review, however,
focuses solely on the role of cytotoxic drugs, for
which, to the best of our knowledge, no data are
currently available regarding their potential role
on the hypothalamic-pituitary axis. Whether
chemotherapeutic drugs can act on the central
endocrine system causing hypopituitarism, pitu-
itary atrophy or other hormonal disorders has
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not yet been demonstrated (42). Clearly, though,
effects such as this could cause detrimental con-
sequences on fertility, and should be investigat-
ed. It is also well recognised that radiotherapy
impacts on uterus development and functionali-
ty (40, 43) but data on the effects of chemother-
apy on clinical uterine function (i.e. pregnancy
outcome) are largely very reassuring (12, 44).
Uteri of patients who received chemotherapy
treatment during childhood were however more
likely to be of smaller volume with poorer vas-
cularization than age-matched healthy controls,
even with normal ovarian function (45, 46).
Both uterine size and blood flow have been as-
sociated with reduced outcome of assisted re-
production treatment (47), but the above data do
not, overall, indicate a major risk for adverse
obstetric outcome. 
Effect of chemotherapy when adminis-
tered during pregnancy 
The concurrence of cancer and pregnancy is a
rare event, occurring only in around 0.1% of all
pregnancies, although the increasing age at
childbearing will likely produce an increase in
its incidence (48). In past years, abortion was
routinely recommended by oncologists, both for
the possibility that the therapy could damage the
fetus and in order not to compromise the moth-
er’s survival. In the majority of cases, both con-
cerns have proven unfounded. When chemother-
apy is administered to pregnant women after the
first trimester, there is no evidence of higher
malformations rate, longer term deficiencies or
health problems in the resulting offspring (49-
52). In addition, with the exception of highly ag-
gressive and systemic tumours that require im-
mediate treatment, there is no evidence that
pregnancy interruption will improve the moth-
er’s survival (53). 
The ability of chemotherapeutic drugs to cross
the placental barrier varies from drug to drug, as
does the degree of cytotoxic damage that they
can produce, with antimetabolites and alkylat-
ing agents thought to be the most teratogenic.
However, fetal damage is also affected by the
developmental stage, with more frequent mal-
formations occurring when cancer therapy is ad-
ministered during organogenesis (48). There is
also evidence from a mouse model that in utero
exposure to alkylating agents could adversely
affect the developing gonads:  CTX exposure
during early pregnancy reduced the number of
PFs in the offspring ovaries and increased folli-
cle activation, which in turn would lead to a fur-
ther faster deprivation of the ovarian reserve
(54). This study, if confirmed in women, would
open new concerns when exposing pregnant
women to chemotherapy.
A further, indirect, effect of cancer treatment on
fertility is the need to postpone pregnancy after
treatment, generally until at least 6 months and
often 2 years after the end of chemotherapy (5).
Survivors of hormone-sensitive breast cancer
are often prescribed tamoxifen therapy for 5 -10
years, further delaying the possibility of subse-
quent motherhood: this duration of delay will
have a significant impact on fertility for many
adult women. However, several studies have
failed to find an increase of reoccurrence/re-
lapse or of lower subsequent life expectancy in
women who become pregnant after breast can-
cer (54, 55), thus this is a complex subject for
discussion between a women and her oncolo-
gist. 
Surprisingly, a report from the American CCSS
has shown that cancer survivors are slightly
more likely than their female siblings to have in-
duced abortion (12), while another American
survey demonstrated that cancer survivors have
a higher risk of undesired pregnancy than the
average population, with that risk increasing
with age. Both of these are thought likely to be
due either to patients underestimating their fer-
tility after cancer treatment (56) or to concerns
about their and their offspring’s health (57). A
similar Danish cohort study also showed a small
increase in the proportion of survivors who opt-
ed for abortion in comparison with their sisters
(58). 
Overall, for those cancer survivors who are like-
ly to remain fertile, contraception counselling is
an important aspect of care (59).
Future directions for fertility damage
assessment 
Large follow-up studies are gradually increasing
our knowledge of the long term effects of
chemotherapy on fertility in children, young
girls and women. However, these data require
long periods of time to be gathered and analy -
sed. The vital information obtained by these
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studies should allow further development of
therapeutic regimens. However, these clinical
studies may not provide clear evidence about
the specific role of any individual drug. Instead,
such knowledge is likely to require either ani-
mal studies, ex vivo human tissue work, or a
combination of the two.  A xenografting mouse
model has been developed using fetal human
ovaries to test drug damage, producing data con-
sistent with CTX ovotoxicity (60). Although this
is a valuable method to directly assess the ovarian
reserve, it is not without issues, such as the pauci-
ty of experimental human material as well as the
on going mitotic division in the fetal germ cell
population of the mid-trimester ovary that was
used, not fully representative of the resting pool of
PFs. Ovarian tissues collected from young or
adult women overcome that problem. Soleimani
et al. (61) tested the effect of doxorubicin (DOX)
on human ovarian cortex collected from patients
undergoing preventive ovarian cryopreservation,
using in vitro and in vivo in xenografted mice
methods. This showed that DOX induces apopto-
sis of primordial and growing follicles, adversely
affecting both oocytes and GCs, as well as dam-
aging stromal vasculature. Our laboratory is un-
dertaking similar investigations using an in vitro
approach to test the effect of chemotherapy drugs
on adult human ovarian cortex. Ovarian cortical
strips collected from consented women undergo-
ing elective Caesarean section have been used to
test the effects of two chemotherapy drugs for
which there is debate about their ovotoxicity,
namely cisplatin and DOX, with results indicating
that both drugs damage early growing ovarian fol-
licles (Figure 2). 
Conclusion
For the majority of women, there is an innate
desire to have children. Infertility can be an un-
wanted consequence of life-saving cancer treat-
ment, and may result in significant emotional
distress, leading to reduced quality of life.
Moreover, even in cancer survivors in whom
fertility is preserved, some women experience
anxiety about their potential future reproductive
capability. Such concerns include fears that the
toxic therapy received could potentially affect
their progeny; that pregnancy could result in a
relapse/recurrence; or that their shorter life ex-
pectancy could lead to a failure to provide ade-
quate childcare. Iatrogenic infertility also nega-
tively impacts on physical well-being. The pre-
mature loss of the ovarian reserve as a side ef-
fect of some chemotherapeutic drug treatments
may lead to an increased rate of cardiovascular
disease and osteoporosis, as well as to increased
mortality rates. Due to all these factors, pre-
serving the reproductive function of cancer sur-
vivors is of utmost importance. The accumulat-
ing kno wledge about the role of chemotherapy
on fertility and pregnancy outcome makes it
possible to reassure many women about their
childbearing potential after cancer treatment, as
well as identifying those patients with higher
risk of infertility. Together, early fertility coun-
selling, investigation of ovarian reserve, the use
of cancer therapies with reduced effect on fer-
tility and fertility preservation techniques (re-
viewed in 62) combine to support the maternal
aspirations of many cancer survivors at risk of
reproductive impairment. 
Figure 2 - Representative microphotographs of human ovarian follicles at preantral stage. Human ovarian cortical strips
were cultured for 6 days in: (A) drug-free medium (control), or in the presence of (B) 5 µg/ml cisplatin and (C) 2 µg/ml
doxorubicin during Day 2 of culture. Follicles in B and C display signs of GCs pyknosis (head arrows) and oocyte damage
(arrows). Scale bars: 25µm. Unpublished data: F Lopes, S Morgan, RA Anderson and N Spears.
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